A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)

This research study is about a condition called Amyotrophic Lateral Sclerosis, often known as ALS or Motor Neurone Disease. ALS is a serious illness that affects nerve cells in the brain and spinal cord, leading to muscle weakness and problems with movement, speaking, and breathing over time. Currently, there's no cure for ALS, so doctors and scientists are always looking for new ways to manage the disease and improve quality of life for those affected.

This specific study is testing a new treatment called AMX0035. It's a 'Phase III' trial, which means it's one of the final steps before a new medicine might be approved for wider use. In this study, doctors want to find out if AMX0035 is safe and if it can help slow down the progression of ALS symptoms over 48 weeks. Half of the participants will receive AMX0035, and the other half will receive a 'placebo', which looks exactly like the study medicine but doesn't contain any active ingredients. This helps researchers fairly compare how well the new medicine works.

The main thing researchers will be looking at is how patients' abilities to do everyday activities change over the 48 weeks. They'll use a special score for this. They will also look at other important things like how long people live, changes in their breathing, and their overall quality of life. By carefully comparing the group taking AMX0035 with the group taking the placebo, the researchers hope to understand if AMX0035 could be a helpful new option for people with ALS.